(Q34831033)

4 August 2017

1 reference

title

The role of antibodies in myasthenia gravis (English)

1 reference

4 August 2017

0 references

1 reference

De Baets M

1

1 reference

4 August 2017

Stassen MH

series ordinal

2

1 reference

4 August 2017

publication date

1 October 2002

1 reference

Journal of the Neurological Sciences

4 August 2017

published in

1 reference

4 August 2017

volume

202

1 reference

4 August 2017

issue

1-2

1 reference

4 August 2017

page(s)

5-11

1 reference

Immunopharmacological disease: a break in tolerance to receptor sites.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Acetylcholine receptors and myasthenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Acetylcholine receptor antibody titer and HLA-B8 antigen in myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Plasmapheresis in myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Muscle autoantibodies in subgroups of myasthenia gravis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Antibodies to skeletal muscle in myasthenia gravis. Part 3. Relation with clinical course and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Neurofilament epitopes in thymoma and antiaxonal autoantibodies in myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Intrathymic pathogenesis and dual genetic control of myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Nucleotide and deduced amino acid sequences of Torpedo californica acetylcholine receptor gamma subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Cutting Edge: Granzyme B Proteolysis of a Neuronal Glutamate Receptor Generates an Autoantigen and Is Modulated by Glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Association of the AChRα-subunit Gene (CHRNA), DQA1*0101, and the DR3 Haplotype in Myasthenia Gravis. Evidence for a Three-gene Disease Model in a Subgroup of Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Pathogenesis of myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Thymomas express epitopes shared by the ryanodine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Acetylcholine receptor antibody in myasthenia gravis: purification and characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Acetylcholine receptor-reactive antibodies in experimental autoimmune myasthenia gravis differing in disease-causing potential: Subsetting of serum antibodies by preparative isoelectric focusing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age-related resistance to EAMG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Inflammation at the neuromuscular junction in myasthenia gravis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

High-efficiency gene transfer into skeletal muscle mediated by electric pulses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900200-9

10.1016/S0022-510X(02)00200-9

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference